534 filings
10-K/A
2023 FY
COCP
Cocrystal Pharma Inc
Annual report (amended)
17 Apr 24
5:00pm
10-K
2023 FY
COCP
Cocrystal Pharma Inc
Annual report
28 Mar 24
8:01am
8-K
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
COCP
Cocrystal Pharma Inc
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
COCP
Cocrystal Pharma Inc
1 Mar 24
Termination of a Material Definitive Agreement
4:15pm
8-K
2eu h5bscsv
8 Jan 24
Regulation FD Disclosure
8:00am
8-K
zdgbank6 yl5gobzx3w9
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
SC 13G/A
b281d5r1znj1mj2ehi9
2 Jan 24
Cocrystal Pharma / SABBY MANAGEMENT ownership change
9:53am
8-K
hij5kp
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
jc0f3 qrpd1pahz2d1
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
rnjp33nde5urexw
4 Dec 23
Regulation FD Disclosure
8:00am
8-K
zin5cu 5oomsa0umyb5e
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
sy0l7d4whh
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
p9i7wvv
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
7ec8h
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
4
piw9b7ukoixbcnvdy
20 Jul 23
Cocrystal Pharma / PHILLIP MD ET AL FROST ownership change
4:05pm
4
mjfpea sqmuz
20 Jul 23
Cocrystal Pharma / Anthony J Japour ownership change
4:05pm
4
2oxhlfi3
20 Jul 23
Cocrystal Pharma / James Joseph Martin ownership change
4:05pm